VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Analyst Ratings
Europe - Frankfurt Stock Exchange - FRA:VX1 - US92532F1003 - Common Stock
376.45 EUR
+3 (+0.8%)
ChartMill assigns a Buy % Consensus number of 76% to VX1.DE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 430.81. This target is 14.44% above the current price.
VX1.DE was analyzed by 39 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about VX1.DE.
In the previous month the buy percentage consensus was at a similar level.
VX1.DE was analyzed by 39 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-07-30 | RBC Capital | Maintains | Outperform |
| 2021-07-30 | SVB Leerink | Maintains | Underperform |
| 2021-07-30 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-07-30 | Piper Sandler | Maintains | Overweight |
| 2021-07-20 | SVB Leerink | Downgrade | Market Perform -> Underperform |
| 2021-07-01 | Raymond James | Initiate | Market Perform |
| 2021-06-14 | SVB Leerink | Maintains | Market Perform |
| 2021-06-14 | Truist Securities | Maintains | Buy |
| 2021-06-14 | Piper Sandler | Maintains | Overweight |
| 2021-06-11 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-06-11 | RBC Capital | Maintains | Outperform |
| 2021-06-11 | Stifel | Maintains | Buy |
| 2021-06-11 | Barclays | Maintains | Overweight |
| 2021-06-11 | Baird | Maintains | Outperform |
| 2021-06-11 | Goldman Sachs | Maintains | Buy |
| 2021-06-11 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-06-11 | Citigroup | Maintains | Buy |
| 2021-04-30 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-04-19 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-02-23 | Baird | Upgrade | Neutral -> Outperform |
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the average price target for VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
39 analysts have analysed VX1.DE and the average price target is 430.81 EUR. This implies a price increase of 14.44% is expected in the next year compared to the current price of 376.45.
What is the consensus rating for VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The consensus rating for VERTEX PHARMACEUTICALS INC (VX1.DE) is 76.4103 / 100 . This indicates that analysts generally have a positive outlook on the stock.